Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00111514

Recruitment Status : Completed

First Posted : May 23, 2005

Last Update Posted : February 15, 2007

Sponsor:

Collaborator:

Bill and Melinda Gates Foundation

Information provided by:

IDRI

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety of the Leish-111f + MPL-SE vaccine given as three injections every 28 days at each of three dose levels of Leish-111f protein, in combination with standard pentavalent antimony therapy in adult patients with mucosal leishmaniasis.

Condition or disease	Intervention/treatment	Phase
Leishmaniasis, Mucocutaneous	Biological: Leish-111f + MPL-SE vaccine	Phase 1

Detailed Description:

Mucosal leishmaniasis is a disfiguring and possibly fatal infection. All available medical therapies require weeks of treatment and cause significant toxicity. In Peru, the standard therapy is daily intravenous (IV) pentavalent antimony (20 mg/kg/day) for 28 days. It appears that Leishmania infections can be eliminated by T helper 1 immune responses. These findings argue that a vaccine that augments mucosal leishmaniasis patients' T helper 1 responses will eliminate the infection and disease. This study is a phase 1, randomized, double-blind, placebo controlled, sequential dose-escalating trial to evaluate the safety and immunogenicity of three injections of 5, 10, or 20 μg of Leish-111f protein + 25 μg of MPL-SE adjuvant given at 4 week intervals as an adjunct to standard chemotherapy with pentavalent antimony (20 mg/kg/day for 28 days) in patients with mucosal leishmaniasis.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	48 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis
Study Start Date :	July 2004
Study Completion Date :	May 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leishmaniasis

Genetic and Rare Diseases Information Center resources: Leishmaniasis

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Occurrence of dose-limiting toxicity
Adverse events

Secondary Outcome Measures :

IgG and T-cell response to Leish-111f vaccine
Leish-111f skin test reactivity
Safety of the vaccine with respect to the clinical course of mucosal leishmaniasis

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with mucosal leishmaniasis confirmed by a positive smear, in vitro culture or PCR test

Exclusion Criteria:

Mucosal leishmaniasis must not involve the vocal cords or cause respiratory distress, and there must be no evidence of other disease.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111514

Locations

Layout table for location information

Peru
Clínica de Leishmaniasis, Hospital Nacional Sur Este EsSalud
Cusco, Peru
Universidad Peruana Cayetano Heredia
Lima, Peru, 100

Sponsors and Collaborators

IDRI

Bill and Melinda Gates Foundation

Investigators

Layout table for investigator information

Principal Investigator:	Alejandro Llanos-Cuentas, MD	Universidad Peruana Cayetano Heredia
Study Director:	Franco M Piazza, MD, MPh	IDRI

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010 Oct 28;28(46):7427-35. doi: 10.1016/j.vaccine.2010.08.092. Epub 2010 Sep 17.

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00111514
Other Study ID Numbers:	IDRI-LMVTC-102
First Posted:	May 23, 2005 Key Record Dates
Last Update Posted:	February 15, 2007
Last Verified:	February 2007

Keywords provided by IDRI:


Leishmaniasis Subunit vaccine therapeutic T-cell pentavalent antimony

Additional relevant MeSH terms:

Layout table for MeSH terms

Leishmaniasis Leishmaniasis, Mucocutaneous Euglenozoa Infections Protozoan Infections Parasitic Diseases	Skin Diseases, Parasitic Skin Diseases, Infectious Skin Diseases Leishmaniasis, Cutaneous

To Top